MedLife S.A.

Environmental & Social Information • Oct 14, 2025

MedLife launches Longevity 100+, the first and largest genetic testing program in the region. The project is dedicated to the assessment of individual disease risks and can change the way the Romanian patient approaches their screening programs, contributing to a healthier life in the long term

• The innovative Longevity 100+ program can mark the beginning of a new era in health, by using genetic testing as an individualized prevention tool, adapted to the needs of each patient and oriented towards optimizing well-being.
• A significant number of more than 4,000 employees and customers of MedLife, BCR, WorldClass and Decathlon, as well as possibly from other companies, are voluntarily enrolling in the program. The testing is offered free of charge by MedLife, as part of an initiative aimed at contributing to the development of Romania's first genetic map, thus providing a solid scientific basis to the Romanian state for the development of public policies and future medical studies. The project will make it possible to identify possible regional differences in disease risks and predispositions for certain diseases.
• With a gradual investment of more than €10 million in state-of-the-art genetic sequencing technology and applied research, MedLife becomes the main catalyst for this transformation, supporting the transition from reactive medicine – in which the patient reaches out to the doctor only when the disease manifests itself – to preventive and personalized medicine, focused on early diagnosis and prevention. MedLife finances this study entirely from its own sources.
• MedLife has recently acquired advanced data storage and processing capabilities from the US. The company intends to gradually demonstrate the value of real-time correlation of the patient's medical history – its previous laboratory results (biochemistry, hematology, immunology) as well as medical imaging investigations (MRI, CT) – with the individual disease risks identified through Low-Pass Whole Genome Sequencing genetic analysis.

Bucharest, October 14, 2025. Romania is going through an essential period of change in the field of health. Increasing pressure on hospitals, the increasing incidence of chronic diseases, high treatment costs and patient expectations overlap with the rapid evolution of artificial intelligence and genetic testing technologies. These transformations create the premises for a fundamental transition: the transition from reactive medicine, in which the patient reaches out to the doctor only when the disease manifests itself, to preventive and personalized medicine, focused on early diagnosis, prevention and improvement of the quality of life. It is the medicine of the individual, which addresses each person, not general typologies such as "the 40-year-old man" or "the 30-year-old woman".

In this context, MedLife, the leader in the private healthcare market in Romania, launches Longevity 100+, the first and largest genetic testing program in the region. The project provides free access to advanced genetic testing for 4,000 people, employees of MedLife, BCR, WorldClass and Decathlon. Depending on the number of volunteers, other companies may be added. The results of the program will form the basis of the first large-scale research study on the genetic particularities of the active population in Romania, with the aim of supporting the development of personalized medicine and longterm prevention policies at national level. The project is financed exclusively by the MedLife Group, from its own sources.

The 4,000 employees will benefit from a complete package that includes genetic testing and personalized medical counseling. Each person will take an advanced genetic test free of charge, performed with the help of state-of-the-art genomic sequencing technology: Low-Pass Whole Genome Sequencing (LP-WGS) on the Illumina NovaSeq X Plus platform, recently purchased, for the first time, by MedLife.

After obtaining the results, each participant will benefit from counseling with a geneticist, who will interpret the genetic profile and guide him with concrete recommendations. In addition, the participants will have access to the MedLife application - where they will be able to follow the results and recommendations, the application having the role of transforming the genetic data into a personalized health plan, adapted to their profile. After all, the genomic profile will be the main source along with the patient's clinical and behavioral information in order to personalize the plan of health measures and interventions by specialists for the most optimal prevention.

The app will correlate each patient's medical history in real time – previous laboratory results (biochemistry, hematology, immunology) as well as imaging investigations (MRI, CT) – with individual disease risks identified by Low-Pass Whole Genome Sequencing genomic analysis. In the coming months, the project will generate relevant results, highlighting the benefits of integrating historical health data with advanced genomic sequencing technologies. As part of the project, MedLife has recently acquired technologies with a high data processing capacity from the United States, in order to be able to analyze and correlate all patients' medical information in a complex way, thus supporting the transition to preventive and personalized medicine.

"We are at a turning point, with an acute need to transform the way we look at health. Medicine is changing rapidly, and those who do not contribute to this transformation risk being left behind. Artificial intelligence and medical technologies open up new opportunities, other horizons, and MedLife will be there. We assume the role of engine of this change in Romania and in the region and, why not, we can even think about global impact.

Longevity 100+ is a unique project, carried out exclusively by MedLife with the help of a team of extraordinary specialists. Basically, we aim to democratize genetic testing, shifting the focus from treating the disease after installation, to identifying risks early. We want to show that anyone, whether "Ioana" or "Răzvan", can monitor their health in a personalized way, not just based on age or risk group. We want genetic testing to be widely accessible, giving Romanians the chance to live longer and healthier.

At the beginning of next year, the program will be expanded with artificial intelligence and the integration of conventional laboratory data and imaging, and we hope to be part of the future of medicine. I am extremely proud that, today, a private entrepreneurial company in Romania has reached such a level, that it can gather a team of high-class specialists and that it can look so far", said Mihai Marcu, CEO & President of the Board of Directors of MedLife Group.

Innovation in prevention

Longevity 100+ allows the identification of over 100 genetic predispositions, of which 75 are common diseases, starting from the most common types of cancers, to metabolic, cardiovascular, neurological, autoimmune, gastrointestinal, renal or ophthalmological conditions. Genetic testing also provides information about characteristics related to lifestyle, physical activity, rest, and mental health. Specifically, the MedLife genetic test will help patients better understand what their body needs for wellbeing. Beyond the results and medical data, this test talks about the balance between body and mind, between the rhythm of life and the need for recovery, between energy and calm. By analyzing how each patient's body reacts to nutrition, movement and rest, MedLife specialists will be able to guide them towards a state of lasting harmony - the basis of an active and healthy life.

The team that will work on this project represents a premiere in Romania: no less than 20 specialists with top expertise come together under one roof, in a private Romanian company founded by entrepreneurs 30 years ago. The scientific coordination is provided by Dumitru Jardan, biologist and doctor of science, and the team includes experts in genetics, bioinformatics and preventive medicine.

"It is a paradigm shift in medicine. MedLife's new genetic testing can help you discover your predisposition to chronic diseases such as metabolic, digestive, cardiovascular or various types of cancer. From a lifestyle perspective, the test helps optimize exercise capacity and recovery processes, shows the predisposition to obesity and can identify any intolerances or deficiencies of the body. It also provides insights into how genetic factors influence sleep, stress response, and metabolism efficiency, providing practical recommendations for a healthy lifestyle and long-term disease prevention", said Dr. Dumitru Jardan, coordinator of the MedLife Molecular Biology Laboratory.

The Longevity 100+ program reflects MedLife's commitment to innovation, prevention, and personal data protection, providing each participant with valuable genetic information in a secure and confidential setting.

"The confidentiality of participants' data is our priority. The results of the Longevity 100+ tests are communicated only to the patient, during the consultation with the geneticist, and cannot be accessed by employers, insurers or other third parties. We work with Ipsos to manage data responsibly and with the law firm D&B David and Baias, PwC's correspondent in Romania, to ensure that all information is protected and processed according to the highest legal and ethical standards.", added Mihai Marcu, CEO & President of the Board of MedLife Group.

Strategic partnerships for a healthier Romania

In this first stage, Longevity 100+ is carried out with the participation of employees from the four companies, who benefit from the genetic tests provided by MedLife free of charge. Their involvement reflects the interest in prevention and the adoption of a healthy lifestyle, as well as the awareness of genetic risk factors.

"We are honored to be part of this unique project, which marks a premiere in Romania. Our employees benefit from access to state-of-the-art technologies and MedLife's expertise – a real privilege and an opportunity to take part in a truly innovative program. " - Andreea Voinea, Chief HR Officer BCR.

"We are excited to be part of the Longevity 100+ initiative, which brings a fresh perspective on how we can take care of ourselves. Our team's participation in such an innovative program perfectly complements our mission to promote not only movement, but also health as an essential part of a balanced lifestyle." - Petru Nemțoi - HR Director, Decathlon Romania.

"For 25 years, World Class Romania has been supporting movement as a foundation of health and wellbeing. We believe in prevention through action, through education and through balance. The initiative launched by MedLife takes this mission further, adding a new level of precision – for the first time, prevention is based on personalized scientific data. We are glad to be able to offer our team and members access to such innovation and a modern perspective on health, which perfectly complements our philosophy: to inspire people to be more active, more often and to take care of their health consciously and responsibly." - Kent Orrgren, CEO World Class Romania.

A new standard for Romanian medicine

Through Longevity 100+, MedLife will not only provide access to state-of-the-art genetic testing, but will also contribute to the creation of Romania's first genetic map that will include the population's disease risks, an essential resource for research, health policies and long-term disease prevention.

The program marks the beginning of a paradigm shift in Romanian medicine, focused on prevention, education and responsibility, which will redefine health-related standards and behaviors among the population.

***

About MedLife Group

MedLife started almost three decades ago, developed healthily and became the largest provider of private medical services in Romania. The Romanian entrepreneurs, who laid the foundations of this company, invested and got involved to bring change in the Romanian health system, believed in innovation and dared to aim as high as possible, in order to offer Romanian patients quality, professionalism, care and respect for their needs.

The company operates the most extensive network of clinics, one of the largest networks of medical laboratories, general and specialized hospitals and has the largest corporate customer base for Health Prevention Packages in the country. It is also, in terms of sales, one of the largest private healthcare players in Central and Eastern Europe.

MedLife Group has a track record of success in terms of both organic growth and growth through acquisitions. Its strong and experienced management team has been able to create and manage these growth opportunities, gaining valuable knowledge and experience that will allow it to find the best path for successful further expansion.

Being a Romanian company with tradition, MedLife has chosen to list on the Romanian Stock Exchange, being a model of listings on the local capital market. It has opened horizons, and through the corporate governance it has implemented, it has inspired other local companies to start on this path and help the development of Romanian capital and the economy. The shares issued by MedLife SA are admitted to trading on the regulated spot market administered by the Bucharest Stock Exchange, Premium Category, bearing the trading symbol "M".

During the pandemic, MedLife managed to play an essential role in society and gain a leading status in monitoring the pandemic through active involvement in the research area.

The company continues to invest in projects with an impact on the local community, in technology and infrastructure. It creates jobs and develops an ecosystem that contributes to the development and maintenance of a healthy Romania.